Author:
Nordgard Silje H.,Alnaes Grethe I.G.,Hihn Björn,Lingjaerde Ole Christian,Liestøl Knut,Tsalenko Anya,Sørlie Therese,Lønning Per Eystein,Børresen-Dale Anne-Lise,Kristensen Vessela N.
Funder
The Norwegian Cancer Society
FUGE Program, NFR
SalusAnsvars Award, Ella
Kristian Nyerrøds Fund
Reference51 articles.
1. 5-fluorouracil: mechanisms of action and clinical strategies;Longley;Nat Rev Cancer,2003
2. Disruption of p53 in human cancer cells alters the responses to therapeutic agents;Bunz;JClin Invest,1999
3. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile;Heggie;Cancer Res,1987
4. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency;van Kuilenburg;Clin Cancer Res,2001
5. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity;van Kuilenburg;Eur J Cancer,1997
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献